

Coordination (OARC) is seeking public comments to assist the IACC in identifying priorities for the 2021–2022 update of the IACC Strategic Plan for Autism Spectrum Disorder (ASD) as required by the Autism Collaboration, Accountability, Research, Education and Support (CARES) Act of 2019. The IACC is requesting public comments on research, services, and policy issues related to the seven topics addressed by the IACC Strategic Plan: Screening and Diagnosis, Biology, Risk Factors, Treatments and Interventions, Services, Lifespan Issues, and Infrastructure and Surveillance. The IACC is also requesting information on two additional issues related to autism described in two supplemental questions that are included in this Request for Public Comment.

**DATES:** Responses to this notice are voluntary and the public comment period will be open from October 1, 2021–November 30, 2021.

**ADDRESSES:** All comments must be submitted electronically via the web-based form at: <https://iacc.hhs.gov/meetings/public-comments/requests-for-information/2021/strategic-plan.shtml>.

**FOR FURTHER INFORMATION CONTACT:** Specific questions about this Request for Public Comment should be directed to: Rebecca Martin by phone at (301) 435–0886 or email at [iaccpublicinquiries@mail.nih.gov](mailto:iaccpublicinquiries@mail.nih.gov).

**SUPPLEMENTARY INFORMATION:** The IACC <http://www.iacc.hhs.gov/> is a federal advisory committee composed of federal and public members that provides advice to the Secretary of Health and Human Services on autism spectrum disorder. The Committee is authorized under the Autism CARES Act of 2019, Public Law 116–60. The law requires that the IACC develop a Strategic Plan for autism research and update the Plan annually. The current IACC Strategic Plan can be viewed at: <https://iacc.hhs.gov/publications/strategic-plan/2019/>. The IACC last provided an update on the progress of the Strategic Plan in 2019, after which the committee went out of session as a new committee was being appointed. The IACC reconvened in July 2021 and is now developing a new update of the IACC Strategic Plan.

The IACC Strategic Plan chapters are organized around seven topic areas that are related to community-focused questions:

- Question 1. How Can I Recognize the Signs of ASD, and Why is Early Detection So Important? (Topic: Screening and Diagnosis)
- Question 2. What Is the Biology Underlying ASD? (Topic: Biology)

- Question 3. What Causes ASD, and Can Disabling Aspects of ASD be Prevented or Preempted? (Topic: Risk Factors)
- Question 4. Which Treatments and Interventions Will Help? (Topic: Treatments and Interventions)
- Question 5. What Kinds of Services and Supports Are Needed to Maximize Quality of Life for People on the Autism Spectrum? (Topic: Services)
- Question 6. How Can We Meet the Needs of People with ASD as They Progress into and through Adulthood? (Topic: Lifespan Issues)
- Question 7. How Do We Continue to Build, Expand, and Enhance the Infrastructure System to Meet the Needs of the ASD Community? (Topic: Infrastructure and Surveillance)

The Committee also seeks public comment related to the two following questions:

- Supplemental Question 1. What are important issues for the IACC to consider with regard to the impact of the COVID–19 pandemic on the autism community?
- Supplemental Question 2. What are important issues for the IACC to consider with regard to the needs of underserved populations within the autism community, including racial and ethnic minorities, economically disadvantaged communities, and rural populations?

**Submission Information.** For each topic/question in the Request for Public Comment, commenters may provide input on what they consider to be the most important research, services, and policy issues and remaining gaps in the subject area covered by that Question.

Please note that the web form will accept a maximum of 1,500 characters (including letters, numbers, punctuation, etc.) per topic area. A valid email address is required for submission, and only one submission per email address will be accepted. If duplicate submissions are received (*i.e.*, form letters), only one example of such a submission will be included in the final set of comments.

The information that commenters provide will become part of the public record; as such, please do not include any personally identifiable or confidential information in the comments. The web form will provide the option of submitting responses anonymously, or the choice to include a name and/or organization associated with the comment. Comments are subject to redaction in accordance with federal policies and the IACC's public

comment guidelines and privacy policy. To view the IACC's public comment guidelines and privacy policy, visit: <https://iacc.hhs.gov/meetings/public-comments/guidelines/>. All comments or summaries of comments received will be made publicly available on the IACC website [www.iacc.hhs.gov](http://www.iacc.hhs.gov) within 90 days of the closing deadline for this notice. Email addresses associated with comments will not be included as part of the public disclosure. After the closing deadline, responses cannot be edited or withdrawn. No basis for claims against the U.S. Government shall arise as a result of a response to this request for information or from the Government's use of such information.

**Instructions.** All comments must be submitted through the web form at <https://iacc.hhs.gov/meetings/public-comments/requests-for-information/2021/strategic-plan.shtml>. Individuals submitting comments will receive an onscreen confirmation acknowledging receipt of the comment, but commenters will not receive individualized feedback or responses from the IACC. Only one comment per email address will be accepted, and if duplicate comments are received, only one example will be provided to the IACC.

Dated: September 30, 2021.

**Susan A. Daniels,**  
Director, Office of Autism Research  
Coordination, National Institute of Mental Health.

[FR Doc. 2021–21883 Filed 10–6–21; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Child Health and Human Development Special Emphasis Panel; Ovarian Physiology.

*Date:* November 1, 2021.

*Time:* 10:00 a.m. to 12:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6701 Rockledge Drive, Room 2131B, Bethesda, MD 20892 (Video Assisted Meeting).

*Contact Person:* Luis E. Dettin, Ph.D., Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Drive, Room 2131B, Bethesda, MD 20892, 301-827-8231, [luis.dettin@nih.gov](mailto:luis.dettin@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.865, Research for Mothers and Children, National Institutes of Health, HHS)

Dated: October 4, 2021.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-21903 Filed 10-6-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Child Health and Human Development Initial Review Group; Population Sciences Study Section.

*Date:* October 18, 2021.

*Time:* 9:00 a.m. to 2:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Drive, Room 2121B,

Bethesda, MD 20892 (Video Assisted Meeting).

*Contact Person:* Christiane M. Robbins, Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Drive, Rm. 2121B, Bethesda, MD 20892, (301) 451-4989, [crobbins@mail.nih.gov](mailto:crobbins@mail.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* National Institute of Child Health and Human Development Special Emphasis Panel; Archiving and Documenting Child Health and Human Development Data Sets.

*Date:* October 18, 2021.

*Time:* 2:00 p.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Drive, Room 2121B, Bethesda, MD 20892 (Video Assisted Meeting).

*Contact Person:* Christiane M. Robbins, Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Drive, Room 2121B, Bethesda, MD 20892, 301-451-4989, [crobbins@mail.nih.gov](mailto:crobbins@mail.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children, National Institutes of Health, HHS)

Dated: October 4, 2021.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-21899 Filed 10-6-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act. To request a copy of these documents, call the SAMHSA Reports Clearance Officer at (240) 276-0361.

#### Project: State Opioid Response (SOR)/ Tribal Opioid Response (TOR) Program Instrument (OMB No. 0930-0384)—Revision

SAMHSA is requesting approval to modify its existing CSAT SOR/TOR Program Instrument by (1) collapsing the original three questions into two questions for clarity and (2) adding ten questions in order to collect information on Congressionally mandated and programmatic activities, and comply with reporting requirements. The program-level information is collected quarterly and entered and stored in SAMHSA's Performance Accountability and Reporting System, which is a real-time, performance management system that captures information on the substance use prevention and treatment and mental health services delivered in the United States. Continued approval of this information collection will allow SAMHSA to continue to meet Government Performance and Results Modernization Act of 2010 reporting requirements that quantify the effects and accomplishments of its discretionary grant programs.

The SOR/TOR programs were first authorized under Title II Division H of the Consolidated Appropriations Act, 2018, Public Law 115-141. SAMHSA anticipates 159 recipients (states, territories, and tribal entities) will participate in these grant programs. Grantee-level data will include information related to: Reported overdose reversals; the purchase and distribution of naloxone; training in the administration of naloxone; implementation of prevention and education activities; outreach activities for underserved communities; and the purchase and distribution of fentanyl test strips. This grantee-level information will be collected quarterly.

The revisions to the tool will enable SAMHSA to better assess grantee accountability and performance on the required education and prevention activities for the SOR/TOR programs. SAMHSA will also use the data collected through the revised tool to implement recommendations resulting from the GAO study, "Drug Misuse: Agencies Have Not Fully Identified How Grants That Can Support Drug Prevention Education Programs Contribute to National Goals (GAO-21-96).<sup>1</sup> Finally, the revisions will assist SAMHSA in providing comprehensive

<sup>1</sup> United States Government Accountability Office. (2020, November). Drug Misuse: Agencies Have Not Fully Identified How Grants That Can Support Drug Prevention Education Programs Contribute to National Goals. <https://www.gao.gov/assets/gao-21-96.pdf>.